The United States Food and Drug Administration (FDA) has mandated a label change for terbutaline that warns against off-label use of the drug to prevent and treat preterm labor because of potentially fatal maternal heart problems.
The U.S. Food and Drug Administration (FDA) has mandated a label change for terbutaline that warns against off-label use of the drug to prevent and treat preterm labor because of potentially fatal maternal heart problems.
The new Boxed Warning and Contraindications alerts healthcare professionals not to give injectable terbutaline for prevention or prolonged treatment (ie, longer than 48 to 72 hours) of preterm labor and not to give oral terbutaline for prevention or treatment of preterm labor.
Based on a review of new data from postmarketing safety reports and the medical literature, FDA concluded that the risk of adverse events to the mother-including increased heart rate, transient hyperglycemia, hypokalemia, cardiac arrhythmias, pulmonary edema, myocardial ischemia, and death-outweighs any potential obstetrical benefit of the drug. The label change is consistent with statements from the American College of Obstetricians and Gynecologists.
Terbutaline-which is approved to prevent bronchospasm accompanying asthma, bronchitis, and emphysema-is sometimes used off label to treat preterm labor and uterine hyperstimulation and, over longer periods, to prevent recurrent preterm labor.
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More
Hyperoxygenation use not linked to neonatal outcomes
April 23rd 2024Recent research evaluated the impact of maternal hyperoxygenation on neonatal Apgar scores, revealing no significant enhancement in outcomes among women with pathologic fetal heart rate tracing and suggesting limited efficacy of hyperoxygenation therapy in this context.
Read More
Study finds antihypertensive treatment reduces uterine fibroids risk
April 23rd 2024A recent study revealed that patients with untreated or new-onset hypertension face elevated chances of uterine fibroid diagnosis, underscoring the potential of antihypertensive therapy in mitigating this risk among midlife individuals.
Read More